Adjuvanted Cell-Based Influenza Vaccine Meets Phase 3 Objectives
A peer-reviewed Phase 3 study of CSL Seqirus’ MF59-adjuvanted, cell-derived, higher-dose quadrivalent influenza vaccine enrolled 7,699 adults aged 50 years or older across eight countries. The investigational vaccine was immunologically superior to an adjuvanted…
